Objective:To evaluate the clinical application performance of the
Clinical Pathway for Neurosyphilis (Trial Version) .
Methods:This was a prospective, multicenter, uncontrolled implementation study. From January 2025 to March 2026, the
Clinical Pathway for Neurosyphilis (Trial Version) was piloted at 16 Chinese neurosyphilis clinical surveillance sentinel sites/member institutions of the Neurosyphilis Research Alliance, the China "Belt and Road" Dermatology Alliance. Data on the performance of the clinical pathway in patients with neurosyphilis were collected.
Results:During the study period, a total of 1 703 hospitalized patients with suspected neurosyphilis were screened, and 485 (28.48%) were diagnosed with neurosyphilis. Among the confirmed patients, asymptomatic neurosyphilis was the most common type (241/485, 49.69%) ; among the patients with symptomatic neurosyphilis, general paresis (95/485, 19.59%) and tabes dorsalis (59/485, 12.16%) were the most common clinical forms. Of the 485 confirmed patients, 438 were enrolled in the clinical pathway, corresponding to an entry rate of 90.31%; the entry rates for tabes dorsalis (59/59) and meningeal neurosyphilis (17/17) reached 100%, whereas entry rates for asymptomatic neurosyphilis (212/241, 87.97%) and other types (7/8, 87.50%) were relatively low. Of the 438 enrolled patients, 430 completed the pathway, with a completion rate of 98.17%; the completion rates for tabes dorsalis (59/59) and other types (7/7) reached 100%, whereas those for general paresis (80/85, 94.12%) and meningeal neurosyphilis (16/17, 94.12%) were relatively low. The overall variation rate was 6.62% (29/438) , with the highest variation rate observed in other types of neurosyphilis (1/7, 14.29%) , followed by asymptomatic neurosyphilis (17/212, 8.02%) . Thirty-seven patients (8.45%) received multidisciplinary consultations, primarily by specialists in neurology and psychiatry for complex comorbidities.Conclusion:The
Clinical Pathway for Neurosyphilis (Trial Version) generally performed well and can be further promoted.